- Home
- BMR vs ANL Comparison
BMR vs ANL Comparison
Compare BMR & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMR | ANL |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | Israel | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.4M | 52.0M |
| IPO Year | 2023 | 2023 |
Fundamental Metrics
Financial Performance| Metric | BMR | ANL |
|---|---|---|
| Price | $1.94 | $1.45 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 122.4K | ★ 1.3M |
| Earning Date | 08-13-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,131,000.00 | N/A |
| Revenue This Year | $21.21 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.96 | N/A |
| 52 Week Low | $1.54 | $0.88 |
| 52 Week High | $4.87 | $2.75 |
Technical Indicators
Market Signals| Indicator | BMR | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 47.64 | 49.40 |
| Support Level | $1.54 | $1.32 |
| Resistance Level | $2.03 | $1.53 |
| Average True Range (ATR) | 0.13 | 0.21 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 75.00 | 33.42 |
Price Performance
Historical ComparisonAbout BMR Beamr Imaging Ltd.
Beamr Imaging Ltd is a video technology and image science software company. It is an innovator of video encoding, transcoding, and optimization solutions that enable high quality, performance, and unmatched bitrate efficiency for video and images. The company is conducted through one operating segment, the optimization technology for video and photo compression. The company operates in Israel, the United States, and the rest of the world, it derives a majority of its revenue from the United States.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.